Check-Cap Ltd

+0.03 (+7.36%)
Other Pre-Announcement

Check Cap Reports Q3 Loss Per Share $0.09

Published: 11/18/2020 13:14 GMT
Check Cap Ltd (CHEK) - Check-cap Reports Third Quarter 2020 Financial Results and Corporate Highlights.
Check Cap Ltd - Investigational Device Exemption Application Submitted to U.S. FDA on November 18, 2020 for Pivotal Study of C-scan.
Check Cap Ltd - Believes That It Has Sufficient Capital to Fund Its Ongoing Operations and Plans for About Next 12 Months.
Check Cap Ltd Qtrly Net Loss per Ordinary Share $0.09.
Check Cap - Plan to Provide Further Investor Update on Timelines for Initiation of U.S. Pivotal Study, Expected in 2021, Following Guidance From FDA.
Check Cap -covid-19 Pandemic Has Affected Co's Ability to Initiate Planned Pivotal Study, Commence Pilot Sales in Israel, Europe in Original Timeframe.
Check Cap Ltd - Cash and Cash Equivalents, Restricted Cash and Short-term Bank Deposits Totaled About $21.7 Million As of September 30, 2020.